FDA
-
-
-
-
-
-
-
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
-
-
-
-
-
-
-
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
-
-
-
-
-
-
-
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
-
-
-
-
-
-
-
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
-
-
-
-
-
-
-
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
-
-
-
-
-
-
-
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
-
-
-
-
-
-
-
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
-
329,912 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

